Endocyte, Inc. Reports Third Quarter 2012 Financial Results and Business Update

Published: Nov 02, 2012

WEST LAFAYETTE, Ind., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced financial results for the third quarter ending Sept. 30, 2012, and provided a business update.

Back to news